通用名称

teduglutide

儿科标签批准日期

2019/5/16 0:00:00

特定指示/秒

Short Bowel Syndrome (SBS) in pediatric patients 1 year of age and older

标签更改摘要

- Safety and effectiveness of Gattex have been established in pediatric patients 1 year to less than 17 years of age who are dependent on parenteral support for the treatment of SBS. - Use of Gattex in this population is supported by evidence from adequate and well-controlled studies in adults, with additional efficacy, safety, pharmacokinetic and pharmacodynamic data in pediatric patients 1 year to less than 17 years of age. There were 41 pediatric patients treated with Gattex: 1 infant (1 year to less than 2 years), 37 children (2 years to less than 12 years) and 3 adolescents (12 years to less than 17 years). - Safety and effectiveness in pediatric patients less than 1 year of age have not been established. - Adverse reactions in pediatric patients were similar to those seen in adults - Information on dosing, adverse reactions, PK parameters and clinical trials.

治疗类别

N/A

立法类型

PREA Only

产品说明书链接

书号

N/A

研究年龄

N/A

学习类型

N/A

研究设计

N/A

登记的患者

N/A

患者分析

N/A

中心的数量

N/A

国家数量

N/A

西班牙裔拉美裔/拉丁裔总计

N/A

非西班牙裔/非拉丁裔总人数

N/A

总数#种族不明

N/A

亚裔学生总数

N/A

黑人总数

N/A

白人总数

N/A

夏威夷或太平洋岛民总数

N/A

美洲印第安人/阿拉斯加本地人总数

N/A

其他种族总计

N/A

未知种族总数

N/A

国家

N/A